Clinical implication of plasma neutrophil gelatinase-associated lipocalin (NGAL) concentrations in patients with advanced carotid atherosclerosis

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 7, 2010, Pages 1035-1041

  Giaginis, Constantinos ^a   Zira, Athina ^a   Katsargyris, Athanasios ^b   Klonaris, Chris ^b   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

atherosclerosis; carotid; medical history; NGAL; risk factors

Indexed keywords

C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTICLE; BLOOD LEVEL; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION THERAPY MANAGEMENT; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SMOKING HABIT; STENOSIS; VASCULAR SURGERY;

ACUTE-PHASE PROTEINS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERTENSION; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 77954220640     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.211     Document Type: Article

References (33)

1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatenase. J Biol Chem 1993;268:10425-10432
2. Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta 2000;1482:1-8.
3. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799-807.
4. Kjeldsen L, Cowland JB. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000;1482:272-283
5. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432: 917-921
6. Yang J, Mori K, Li JY, Barasch J. Iron lipocalin and kidney epithelia. Am J Physiol Renal Physiol 2003;285:F9-18.
7. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10:1033-1043
8. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008;241:89-94.
9. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52:595-609.
10. Soni SS, Ronco C, Katz N, Cruz DN. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 2009;28:165-174
11. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2006;1:328-331
12. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38:64-80.
13. Niessner A, Goronzy JJ, Weyand CM. Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations. Curr Pharm Des 2007;13:3701-3710
14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143
15. Spagnoli LG, Bonnano E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007;48:1800-1815
16. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136-142
17. Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl AL, Hamsten A, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemost 2007;98:427-433
18. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84.
19. Anwaar I, Gottsater A, Ohlsson K, Mattiasson I, Lindgarde F. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMO in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 1998;8:310-317
20. Falke P, Elneihoum AM, Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis 2000;10:97-101.
21. Forsblad J, Gottsater A, Persson K, Jacobsson L, Lindgarde F. Clinical manifestations of atherosclerosis in an elderly population are related to plasma neopterin, NGAL and endothelin- 1, but not to Chlamydia pneumoniae serology. Int Angiol 2002; 21:173-179
22. Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:22533-22540
23. Liapis CD, Bell PR, Mikhailidis D, Sivenius J, Nicolaides A, Fernades e Fernades J, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indication, techniques. Eur J Vasc Endovasc Surg 2009;37:1-19.
24. Howard G, Prineas R, Moy C, Cushman M, Kellum M, Temple E, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the reasons for geographic and racial differences in stroke study. Stroke 2006;37:1171-1178 (Pubitemid 43731857)
25. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580
26. Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009;30:1229-1236
27. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41.
28. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kB. Am J Pathol 2006;169:2245-2253
29. Watson K, Watson BD, Pater KS. Peripheral arterial disease: a review of disease awareness and management. Am J Geriatr Pharmacother 2006;4:365-379
30. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease. J Inherit Metab Dis 2006;29:3-20.
31. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996;27:1734-1738
32. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol 2005;6:2.
33. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009;104:917-920